~25 MILLION MITE PARTIES HAPPENING NOW*

illustrated map of use covered in map pin icons next to four demodex mites holding party favors

Images are character representations of Demodex mites.

Demodex Blepharitis (DB): What You Should Know About This Common Eyelid Disease

Demodex blepharitis—also known as DB—is an eyelid disease caused by an infestation of Demodex mites, a common mite found on humans.^1,2

Locate DB-knowledgable eye doctors in your area with our
Find an Eye Doctor tool.

Image Credit: Laura Periman, MD

*It’s estimated that approximately 25 million eye care patients in the US are affected by DB.^3,4

Crusties (collarettes) around the base of the eyelashes signal a DB condition.^1,3

Symptoms of DB can easily be overlooked by patients due to symptom similarities with other eye diseases.¹

When left untreated, DB can leave you more prone to other eye-related diseases.¹

Common signs and symptoms of DB can include eyelid redness, crusties (collarettes), irritation, misdirected eyelashes, and inflammation.^1–3

closeup shot of eyelid afflicted with demodex blepharitis db

illustrated demodex mite standing next to upright clipboard

DEMODEX BLEPHARITIS IMPACT CHECK

Answer a few questions to uncover the effects of DB.

TAKE QUIZ NOW

CONNECT WITH THE XDEMVY COMMUNITY

Unite With XDEMVY: Updates, support, and a community awaits.

JOIN THE COMMUNITY

Illustrated demodex mite peers around a bottle of XDEMVY next to party favors in a puddle of liquid

One drop per eye, twice a day (~12 hours apart), for 6 weeks.

TREATMENT WITH XDEMVY

You can address the root cause of DB.

LEARN MORE

two illustrated demodex mites are paralyzed one says uh oh in speech bubble with text reading party’s over

References

References: 1. Fromstein SR, Harthan JS, Patel J, Opitz DL. Demodex blepharitis: clinical perspectives. Clin Optometry. 2018;10:57-63. 2. Rhee MK, Yeu E, Barnett M, et al. Demodex blepharitis: a comprehensive review of the disease, current management, and emerging therapies. Eye Contact Lens. 2023;49(8):311-318. 3. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Ophthalmol. 2022;16:1153-1164. 4. O’Dell L, Dierker DS, Devries DK, et al. Psychosocial impact of Demodex blepharitis. Clin Ophthalmol. 2022;16:2979-2987.

Important Safety Information

Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis. 

Handling the Container: Avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

When to Seek Physician Advice: Immediately seek a physician’s advice concerning the continued use of XDEMVY if you develop an intercurrent ocular condition (e.g., trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions. 

Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.

To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals at 1-888-421-4002 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

~25 MILLION MITE PARTIES HAPPENING NOW*

Demodex Blepharitis (DB): What You Should Know About This Common Eyelid Disease

DEMODEX BLEPHARITIS IMPACT CHECK

CONNECT WITH THE XDEMVY COMMUNITY

TREATMENT WITH XDEMVY

You are leaving the XDEMVY® patient website and going to the Tarsus Pharmaceuticals, Inc. corporate website.

You are leaving the XDEMVY® patient website and going to the healthcare professional website.

You are leaving the XDEMVY® patient website.

Are you a US healthcare professional?

You are leaving the XDEMVY^® patient website and going to the Tarsus Pharmaceuticals, Inc. corporate website.

You are leaving the XDEMVY^® patient website and going to the healthcare professional website.

You are leaving the XDEMVY^® patient website.